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0. Abstract 
Although phosphatidylserine (PS) confined to the inner leaflets of plasma membrane 
is exposed on the cell surface when cells undergo apoptosis, viable cells also 
externalize PS in certain cellular states. However, the pathophysiological 
significance of PS exposure on viable cells remains elusive. Through imaging 
analyses, we found that PS was exposed on the plasma membrane of live mast cells 
(MCs) during degranulation. Although the exposed PS did not promote phagocytes 
engulfment of live MCs, it colocalized with CD300a, an inhibitory immunoreceptor 
that recognizes PS. Fluorescence resonance energy transfer (FRET) experiment 
reveals the direct cis-binding between CD300a and PS during degranulation. 
Functionally, I observed that degranulation was greater after stimulation with an 
IgE–antigen complex in MCs deficient in CD300a than in wild-type MCs. 
Pretreatment of MCs with a neutralizing anti-CD300a antibody efficiently 
upregulated the degranulation of wild-type MCs as a result of interference of cis-
interaction between CD300a and PS as evidenced by decreased FRET efficiency. 
Consistently, CD300a-deficient mice or in vivo treatment with a neutralizing 
CD300a antibody showed slower recovery of body temperature compared with wild-
type mice in MCs-dependent passive systemic anaphylaxis. Our study suggests self-
regulation of MC degranulation through cis-interaction of PS with CD300a to down 
regulate allergic response, adding another layer of regulation in allergic responses. 
 
Keywords: Phosphatidylserine; mast cell degranulation; CD300a; self-regulation  
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1. Introduction 
1.1 Mast cells and allergic response 
Mast cells (MCs) are one of the evolutionally conserved cell types among all the 
vertebrate1. First described by German physician Paul Ehrlich in 1878 based on its 
unique cellular morphology with granules and the ability to retain basic aniline dyes, 
MCs are widely distributed among many tissues, including vital organs such as 
brain, intestine, skin and lungs. The heterogenicity of MCs is now a well-established 
concept, as two distinct MCs populations – mucosal-type MCs and connective 
tissue-type MCs – could be defined in rodents based on their different expression 
profile of MCs protease2; and three different populations of human MCs are 
proposed by their different serine proteases expression, namely, tryptase-only 
(MCT), chymase-only (MCC), and tryptase and chymase double positive (MCTC) 
MCs3. 
It is now appreciated for MCs’ important roles in mammalian physiology and 
pathology4. Despite the increasing research interests of MCs roles in normal 
physiology, such as angiogenesis, tissue remodeling, wound healing and immune 
regulation, the effector function of MCs activation in allergic response remain to be 
a significant research area5 . 
Although MCs are the major effector cell type involved in IgE-dependent 
allergic responses, the link between MCs activation and allergic symptoms (e.g. 
anaphylactic shock) was only established half century later after the discovery of 
MCs, when histamine and heparin, the major effector molecules for anaphylactic 
shock, were found mainly released from MCs by series works from Riley and West 
in 1950s6–8. In 1966 and 1967, K Ishizaka and T Ishizaka found IgE and their 
reactivity to specific allergen were correlated and responsible, respectively, of the 
 5 
hypersensitivity-induction activity from atopic patients9,10. The successful culture of 
rat basophilic leukemia cell line (RBL) later on enabled the detailed characterization 
of IgE-binding property of basophil and mast cell, as well as the histamine release 
from some RBL cells after IgE binding11,12 . Finally, in 1989, the complete structure 
of high affinity IgE receptor FcεRI was cloned and expressed13.  
It is clear now that antigen-specific IgE sensitize MCs through binding to the 
IgE binding site on α chain of FcεRI. The presence of multivalent antigen aggregates 
more than one FcεRI. The colligation of this receptor activates MCs and cause the 
release of pro-allergic substances, a process termed “degranulation”, as the granules 
which contain the pre-stored pro-allergic substances, are released during such MC 
activation. Besides histamine and heparin, the activation of MCs also triggers the 
release of a large panel of other effector molecules, including cytokines, such as 
TNF-α13 and various proteases13. Activated MCs are also capable of releasing lipid 
mediators, chemokines and growth factors through de novo synthesis14,15. The 
released mediators play important roles in not only allergic responses, but also 
bacteria killing16,17, leukocyte recruitment 18,19 and adaptive immune response 
induction20. 
The importance of MCs in physiology and pathology is revealed using MC-
deficient mice as powerful research tools21–23. Indeed, MC-deficient mice are 
completely protected from IgE-mediated passive systemic anaphylactic shock, 
highlighting the vital role of MCs as effector cells during anaphylactic shock24. 
Reconstituting MCs in MC-deficient mice is a compelling method to dissect the 
critical pathways and regulatory components involved in MC degranulation, allergy 
and anaphylaxis. CD300lf and Allergin-1, for example, are inhibitory receptors on 
MCs and inhibit FcεRI-mediated degranulation. Transfer of CD300lf24 or Allergin-
125 deficient MCs into MC-deficient mice showed more body temperature decrease 
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than wild-type MCs-transferred group in a passive systemic anaphylaxis (PSA) 
model, confirming the inhibitory function of these receptors in vivo. Using such 
strategy, studies identified many factors regulating mast cell degranulation and their 
further implications in allergy and anaphylaxis26–28. 
 
1.2 Mast cell degranulation machinery and its regulation by inhibitory 
receptors 
On MCs, FcεRI is composed of one each of α and β chain with two γ chains. β and γ 
chains contain immunoreceptor tyrosine-based activation motifs (ITAMs). Upon 
colligation, ITAMs in both β and γ chains are quickly phosphorylated by the Src 
family kinase Lyn, which is constantly associated with β chain. The phosphorylation 
of ITAMs results in the Syk recruitment to the γ chain and Syk phosphorylation. 
Phosphorylated Syk further phosphorylate other adaptor proteins and kinases in the 
signal cascade, including phospholipase C gamma (PLC γ), a key molecule to 
catalyze the hydrolysis of phosphatidylinositol bisphosphate to inositol trisphosphate 
(IP3) and diacylglycerol (DAG), which result in cytosolic Ca2+ mobilization and 
protein kinase C (PKC) activation, respectively. The activated PKC further 
phosphorylate the light chain of myosin within the actin-myosin complex under 
cytoplasm membrane and cause the disassembly of the complex. SNARE complex is 
formed as a result of increased cytosolic calcium and the inactivation of its inhibitory 
machineries by activated PKC. Formed SNARE complexes mediate the membrane 
fusion between granules and cytoplasmic membrane, which results in the release of 
processed granule contents as well as the change of surface markers of the 
cytoplasmic protein (Fig. 1).29  
The consequences after granules and cytoplasm membrane fusion provide 
sensitive and complementary methods for measuring the degranulation 
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experimentally. For example, the release of histamine30, serotonin31 , catalytic 
enzymes (e.g. beta-hexosaminidase)32 and cell surface expression of endosomal 
markers (e.g. LAMP-1)33 are frequently used for such propose. 
The degranulation process is a well-organized cellular and molecular event 
with the cooperation among various pathways and signaling molecules 
aforementioned. The defects of certain components involved in this event will cause 
the altered degranulation and subsequent change of in vivo phenotype (e.g. allergic 
response, anaphylaxis)33 . For example, the genetic deletion of FcεRI α chain causes 
a complete loss of degranulation of MCs and therefore the MCs-deficient mice 
receiving a transfer of FcεRI α-deficient MCs are protected from allergic symptoms 
in a food allergy model27. 
The deficiency of src-famlimy kinase Lyn, however, generates confusing 
results with decreased34,35, increased35,36 and comparable37 degranulation in vitro, as 
well as controversial phenotypes in vivo. This is probably because of the multiple 
functions of Lyn to process inhibitory phosphorylation on C-terminal Src kinase 
(Csk)-binding protein (Cbp)36  and on the FcεRI β chain35 , as well as the increased 
activation of SHIP-1 phosphatase activity in Lyn-deficient MCs38.  
The Syk-deficient MCs showed defect to phosphorylate both PLCγ1 and 
PLCγ2 and failed to increase the cytosolic calcium concentration upon FcεRI 
activation and failed to degranulate39. Similarly, PLCγ2 deficient MCs showed 
impaired calcium mobilization, therefore a decreased degranulation in response to 
FcεRI stimulation40.  
The pathology of allergic diseases and anaphylaxis is largely contributed by 
mast cell degranulation triggered by FcεRI activation24,41. Therefore, the specific 
inhibitory machinery of degranulation is thought to be of therapeutic 
significance42,43. Indeed, many approaches showed promising results in inhibiting the 
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MCs degranulation, including using the inhibitors of key signaling pathways44,45, 
modulation of actin-regulatory proteins46 and cell intrinsic SNARE inhibitory 
proteins47 as well as ITIM-bearing cell surface receptors42,48.  
Because the molecules involved in degranulation signal transduction and 
machinery are often found to be universally expressed in other cell types and have 
fundamental functions in steady state (e.g. SNARE49 proteins and actin50), which 
rendered their specificity for targeting MCs degranulation. On the other hand, MCs 
naturally express many inhibitory receptors which bearing the immunoreceptor 
tyrosine-based inhibition motif (ITIM) in their cytoplasmic domains (e.g. FcRIIB51, 
gp49B152, SIRPα53, LILRB254, CD300a55, CD300lf56  and Allergin-125). These 
receptors are expressed on more specific cell populations and specifically be 
activated in the presence of their ligands or agonistic antibodies42.  Upon activation, 
phosphorylation of tyrosine residues in ITIMs enables the recruiting of phosphatase 
such as SHP-1, SHP-2 and/or SHIP, which will dephosphorylate several kinases and 
their downstream targets of the FcεRI pathway, thus suppresses MC activation. For 
example, colligation of FcεRI with ITIM bearing receptors, such as gp49B152, 
CD300lf57 and Allergin-125 with receptor-specific monoclonal antibodies, showed 
effective decrease of FcεRI-mediated mast cell degranulation without obvious 
requirement of their natural ligands. 
Among the inhibitory receptors on MCs, LILRB2 is able to suppress FcεRI-
mediated mast cell degranulation without colligation with FcεRI. Indeed, the ligand 
of LILRB2 is found to be MHC-I, which is originally expressed on the same cell and 
form constant cis-interaction and activation of LILRB2. Such cis-interaction may 
regulate the activation threshold of MCs54 .  
In contrast, CD300lf shows intriguing requirement of its proposed ligands for 
inhibitory function. Izawa and colleagues identified ceramide as natural ligands of 
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mouse CD300lf and blocking interaction of ceramide and CD300lf by an anti-
ceramide antibody effectively abolished the inhibitory function of CD300lf in a 
passive cutaneous anaphylaxis model, resulting in elevated vascular leakage57. 
Indicating the inhibitory function of indigenous ceramide through its receptor 
CD300lf, intriguingly however, exogenous administration of ceramide could also 
negatively regulate MCs function in the same model in a CD300lf dependent 
manner57, raising a question of the relative importance of indigenous ceramide in 
CD300lf function. 
Although therapeutically effective, in many cases, the physiological 
significance of those inhibitory receptors on MCs remains unknown due to lack of 
knowledge of their natural ligands42,48, proposing a big challenge for therapeutically 
targeting. (Fig. 1) 
 
1.3 PS exposure during apoptosis and cell activation 
Eukaryotic cell membrane is composited of lipids, proteins and carbohydrates, with 
the lipid bilayers as scaffold, membrane proteins stay in or anchored on the lipid 
bilayer and carbohydrates mainly exist as glycolipid or glycoprotein58. The lipid 
compartment is mainly consisted of phospholipids, sphingolipids and sterols59. 
Although the exact composition of lipids differs across cell types and status, the 
major structural lipids in eukaryotic membrane is phospholipids: 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylinositol (PI) and phosphatidic acid (PA), with PC as dominant 
component (>50%) 59,60. One important feature of the lipid bilayer is the asymmetric 
distribution of lipid components on live cells, with consists predominantly of PC, 
sphingomyelin, and glycolipids dominant the outer leaflet, whereas the inner leaflet 
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contains PE, PS and PI and cholesterol is distributed in both leaflets58. The 
asymmetric distribution is largely due to the P4-ATPases flippase activity, which 
translocate the aminophospholipids PS and PE towards the cytosolic leaflet61,62. 
However, PS is exposed on the surface after death induction (e.g. apoptosis) or cell 
activation63–66.  
During cell apoptosis, PS exposure can be triggered by the inactivation of 
flippase as well as the activation of scramblase, a group of enzymes functioning to 
transport lipids following the existing lipid gradient without specificity and direction 
between the inner and outer leaflets67,68. Nagata’s group identified a caspase 
cleavage site in a flippase ATP11C and a scramblase Xkr8. The activation of caspase 
during apoptosis causes the cleavage and inactivation of ATP11C together with 
cleavage and activation of Xkr8 and lead to the exposure of PS during apoptosis; 
indeed, a mutation on the caspase cleavage site maintained the ATP11C flippase 
activity or suppressed Xkr8 activation during apoptosis and results in lack of PS 
exposure and resistance to phagocytosis 69,70.  
Upon cell activation, Elliott and colleagues found that PS can be exposed on 
CD45RB negative T cell population as well as T cell activated through P2X7 
receptor by ATP64. Similarly, the same group also reported that B cell PS exposure is 
also negatively correlated with CD45 phosphatase activity, as CD45-deficient B cells 
expose PS constantly on their surface63. Interestingly, PS exposure on activated 
platelets is caused by the increased cytosolic calcium concentration, where a 
calcium-dependent scramblase TMEM16F is activated in high calcium environment. 
Lack of TMEM16F dampens the PS exposure during platelet activation71. Indeed, a 
constitutive active form of TMEM16F is enough to expose PS on the cell surface 
when transduced into lymphoma cell72.  Although, the responsible flippase and/or 
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scramblase remain unknown in both PS+ live T and B cells, PS exposure on activated 
T cell was also correlated with increased cytosolic calcium64 , pointing out the 
possibility for a calcium-dependent scramblase during PS exposure of activating T 
cell. 
 
1.4 The function of apoptotic PS exposure 
PS exposed on apoptotic cell is well-known as an “eat me” signal which promotes its 
recognition and engulfment by macrophages73,74. Accordingly, macrophages express 
receptors recognizing PS (e.g. Tim-4) and bridging proteins binding to PS (e.g. 
ProteinS, Gas6) to mediate receptor tyrosine kinase Tyro3/Axl/Mer (TAM)-
dependent phagocytosis75. PS exposure on apoptotic cells is an important factor 
contributing to phagocytosis, since incubating apoptotic cells with PS masking 
molecule, Annxin-V76 or a mutated Milk fat globule-EGF-factor 8 (MFG-E8-
D89E)77 efficiently decreased the phagocytosis of apoptotic cells by macrophages. 
Nagata’s group proposed a “two-step” engulfment model for apoptotic cell 
phagocytosis, tethering and engulfing. PS may participate in both steps, as in an 
artificial Baf3 phagocytes expressing PS receptor Tim4 and integrin α(v)β(3), Tim-4 
function as tethering through PS binding and integrin α(v)β(3) complex together 
with MFG-E8 mediate engulfment78,79. However, a recent study reported that Tim-4 
may not be required for all the phagocytosis events in some types of macrophage80 
as Mer can function in both tethering and engulfing steps81.  
Besides functioning as an “eat me” signal, PS exposed on apoptotic cells also 
functions as a ligand for the PS receptor CD300a, expressed on many myeloid cells 
including MCs and dendritic cells (DCs). Nakahashi-Oda and colleagues found that 
PS from apoptotic epithelial cells bind to the same PS receptor CD300a on CD11b+ 
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intestinal DCs and effectively suppressed TLR-4-TRIF-mediated interferon-β (IFNβ) 
production, a cytokine involved in regulatory T cell abundance. In an in vitro co-
culture system of DCs and apoptotic cells, masking PS by MFG-E8-D89E 
dramatically increased the IFNβ from DCs to the similar level as CD300a deficient 
DCs after fecal contents stimulation82. Apoptotic cells are known for their immune 
regulatory ability83, this finding highlighted the immune modulatory ability of 
apoptotic PS and its sensing machinery, as represented by a PS receptor CD300a.  
 
1.5 The function of live cell PS exposure 
As an “eat me” signal, PS-coated beads or PS liposomes can be effectively 
phagocytosed by macrophages84–86, paradoxically, PS-exposing live cells are not 
sufficient to trigger phagocytosis, as a constitutive active scramblase-expressing 
lymphoma cell line, which expose comparable level of PS with that on apoptotic 
cells failed to be engulfed by phagocytes both in vivo and in vitro72. On the other 
hand, a recent report from the same group observed a loss-of-function mutation in 
flippase ATP11C conferred the PS exposure on live pre-B cells and pre-B cell-
specific engulfment by macrophages in a PS-dependent manner87. It seems the 
flippase inactivation or scramblase activation induced PS exposure on living cell 
may differ from each other in the stability of surface PS and result in the distinct 
outcome of phagocytosis69,73. 
Despite the intriguing role of live cell exposed PS in live cell engulfment, the 
functions of PS exposed on activated platelet and T cells were investigated by 
different groups.  
PS on activated platelets provides interacting platform for factor Va and Xa, 
interacts with proteins in prothrombinase complex and promotes its assembly65,88, 
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explaining previous observation that PS-containing vesicles can sufficiently induce 
activation of prothrombinase in an in vitro artificial system89. Platelet incapable of 
exposing PS after activation due to a lack of scramblase TMEM16F failed to induce 
coagulation and mice with TMEM16F deficiency suffered from mild bleeding71. 
On T cell activated by ATP, PS exposure was shown to correlate with 
CD62L shedding64. In the same study, blocking PS by Annexin-V, inhibited the T 
cell migration both in vitro and in vivo64.  However, the responsible molecules 
directly involved in PS translocation and recognition are still unknown. Moreover, 
PS exposure and its function on B cell are still controversial63,90,91. 
  
1.6 CD300a on MCs and live MCs PS exposure 
MC is known to be AnnexinV positive upon FcεRI co-ligation induced 
degranulation 66,92,93. The PS exposure is not associated with cell death and is 
reversible within 24 hr after stimulation66,93. However, the detailed characteristic 
(e.g. time scale, intensity) and physiological functions of PS externalization on MC 
remain elusive94. 
Interestingly, MCs highly express PS receptors CD300a which has three 
ITIMs in its cytoplasmic region55 and was shown to be a receptor of 
phosphatidylserine (PS), which is expressed on apoptotic cells95. Nakahashi-Oda and 
colleagues reported that PS from apoptotic cells can robustly suppress the TLR-4-
MyD88-mediated pro-inflammatory signals on MCs through interaction with MC 
CD300a. This suppression reduced the proinflammatory cytokine production in MCs 
during a murine sepsis model, rendered bacteria clearance and led to increased 
mortality19. Blocking CD300a and apoptotic PS interaction by a blocking antibody 
against CD300a or PS masking molecule MFG-E8-D89E, abolished the inhibitory 
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function of CD300a19.  This study highlights the importance of CD300a in sensing 
apoptotic cells and mediating the immunosuppressive function during severe 
inflammation where apoptotic cells are abundant, however, apoptotic cells are 
quickly removed by phagocytes and therefore absent in normal tissue96, raising a 
curiosity of CD300a function on MCs activation during non-inflammatory condition.  
Despite the suggestions by many researchers that CD300a may play an 
inhibitory role in MC degranulation through its intracellular ITIM motifs after 
colligation with FcεRI receptor 94,97, little is known about the physiological function 
of CD300a on FcεRI-mediated MCs degranulation, especially the interaction 
between CD300a and its natural ligand PS, which is exposed during the 
degranulation.  
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2. Purpose of this study 
Characterization of PS exposure during FcεRI-mediated MCs degranulation; 
functional analysis of externalized PS during MCs activation from the view of PS 
receptor CD300a.  
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3. Materials and methods 
3.1 Cells 
Bone marrow (BM)-derived cultured MCs (BMMCs) were generated by culturing 
wild-type (WT) and Cd300a-/- mouse BM cells in the presence of 10 ng/ml stem cell 
factor (SCF) (455-MC/CF, R&D Systems) and 4 ng/ml IL-3 (403-ML, R&D 
Systems) as previously described25. Briefly, weekly passages were performed by 
seeding 2 × 106 cells in 10 ml medium. Cells were cultured for 5 to 8 weeks before 
use. Cd300a-/- mice were described previously 25. Cultured human synovial MCs 
were prepared and maintained as previously reported 98. All mice experiments were 
conducted in accordance with the guidelines of the animal ethics committee of the 
University of Tsukuba Animal Research Center. The human mast cell study was 
approved by the Ethics Committee of the Nihon University School of Medicine (RK-
160112-2), and all the subjects provided written informed consent in accordance 
with the Helsinki Declaration of the World Medical Association. 
 
3.2 Antibodies, other reagents, and flow cytometry  
Anti-mouse CD107a (1D4B), anti-mouse c-Kit (2B8), anti-mouse IgE (RME-1), 
mouse IgG1 (MOPC-21), anti-human CD107a (H4A3), anti-Flag (L5) antibodies 
and FITC-Avidin were purchased from Biolegend. Human IgE Myeloma (401152) 
was purchased from CALBIOCHEM. Anti-human IgE (Dε2) (E124.2.8) was 
purchased from BECKMAN COULTER. Annexin V, Trinitrophenyl (TNP)-specific 
mouse IgE (C38-2) was purchased from BD Bioscience. Anti-Syk (#2712) and anti-
pSyk (#2711) antibodies were purchased from Cell Signaling Technology. TNP–
ovalbumin (OVA), MFG-E8-D89E, MFG-E8-EPT, neutralizing and non-
neutralizing anti-mouse CD300a antibodies (EX42 and TX10, respectively), 
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CD300a-human Fc protein and anti-human CD300a (mouse IgG1, TX49) were made 
in our laboratory, as previously described 55,95. 1-oleoyl-2-{6-[(7-nitro-2-1,3-
benzoxadiazol-4-yl) amino] hexanoyl}-sn-glycero-3-phosphoserine (NBD-PS) was 
from Avanti. Lipopolysaccharide (LPS; L2880) derived from Escherichia coli 
O55:B5, ATP (A26209), Ionomycin (I9657) were purchased from Sigma-Aldrich. 
PSVue480 and PSVue643 were purchased from Molecular Targeting Technologies. 
Recombinant mouse IL-33 was purchased from R&D (3626-ML).  
CD300a-Fc blocking experiment was done with either apoptotic cell induced 
by dexamethasone or degranulated BMMCs. Briefly, 105 cells were incubated with 
CD300a-Fc together with 50ng anti-CD300a antibody (TX10 or EX42) or 100ng 
MFG-E8-D89E on ice for 15min, and further stained by anti-CD107a (for BMMCs 
only) and anti-human IgG Fc-PE (M1310G05, Biolegend) and PI. 
Flow cytometry analyses were performed using a LSRFortessa system (BD 
Bioscience), and data were analyzed by using FlowJo software (BD). 
 
3.3 Degranulation and other stimulations 
For mouse in vitro stimulations, MCs were sensitized with 1 μg/ml TNP-specific IgE 
overnight, washed twice with Tyrode’s buffer, pre-incubated with reagents as 
indicated for 30min, and then challenged with 1ng/ml TNP–OVA for 30min or 
indicated time point. β-Hexosaminidase activity was measured as previously 
reported 25. Briefly, 50 μl of the culture supernatant was mixed with 50 μl of 4-
nitorophenyl-N-acetyl-β-D-glucosaminide (1.3 mg/ml; Sigma, N9376) in substrate 
buffer (0.4 M citric acid, 0.2 M NaH2PO4, pH 4.5) and incubated at 37°C for 3 h. 
The reaction was stopped by adding 100 μl of glycine (0.2 M, pH 10.7), the solution 
was thoroughly mixed, and then absorbance of 415 nm was determined. CD107a 
was measured by flow cytometry after staining with anti-cKit and anti-CD107a 
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antibodies and PI. Apoptotic thymocytes were induced in 0.2mM dexamethasone 
with 107 cell/ml RPMI medium for 12 hr. Cell density pictures were acquired under 
20X objective lens under bright field and converted into binary by ImageJ. 
For human MCs stimulation, cultured human synovial MCs were sensitized 
with 500ng/ml human IgE, stained with 50ug/ml anti-human CD300a or isotype 
control antibody, challenged with 300ng/ml anti-human IgE antibody for 30min, 
followed by staining with anti-human CD107a and PI, and analyzed by flow 
cytometry.  
For measuring PS exposure of BMMCs after stimulations by LPS (1 μg/ml), 
IL-33 (150 ng/ml), TNP-OVA (10 ng/ml), ATP (0.5 mM), or ionomycin (2500 
ng/ml), the cells were incubated with indicated reagents for 20 min after IgE 
sensitization and then stained with antibody against CD107a, annexin V and PI. For 
measuring degranulation after ATP (0.5mM) or ionomycin (500ng/ml) stimulation, 
the stimulation time was 30min.  
 
3.4 Live imaging 
For time lapse-imaging, BMMCs were sensitized as mentioned above and then 
incubated in 500 µl of Tyrode’s buffer containing 1 mM PSVue-643 fluorescent 
probe (Polysciences, Inc.) in a glass-bottom dish (CELLview, Greiner Bio-One) for 
30 min before gently adding 10 μl of TNP–OVA (100 ng/ml). Cells were monitored 
under a laser scanning confocal microscope (Olympus FV10i) at 10 s intervals under 
60× optical magnification. Data were analyzed and exported by FV10-ASW 
(Olympus). The video and montage were generated by ImageJ software with 10 
frames/s. The confocal images of single mast cells were also collected and analyzed 
on the same platform with PS stained by PSVue480 and CD300a by Alexa647 
conjugated anti-CD300a. 
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For imaging flow cytometry, the Image Stream Mark II system (Amnis) was 
used to observe single cells after 15min degranulation and staining. Data were 
acquired and analyzed by using the Inspire and Ideas software packages (Merck), 
respectively. The Bright Detail Similarity R3 Feature (based on Pearson correlation 
coefficient) was adopted as the localization measurement according to the 
manufacturer’s instructions. Briefly, the Bright Detail Similarity R3 Feature value 
was calculated with a customized imaging mask to identify aggregation of the 
molecule of interest (CD107a or PS) on the cell surface. To detect colocalization of 
CD107a and PS, the mask was set on the CD107a channel with the following 
parameters: Threshold (M05, Ch05, 73) & Peak (M05, Ch05, Bright 10). To detect 
colocalization of CD300a and PS, the mask was set on the PS channel with 
following parameters: Threshold (M05, Ch05, 60) & Peak (M05, Ch05, Bright 4). 
The data were exported as an FCS (Flow Cytometry Standard) file and analyzed by 
FlowJo (TreeStar).  
For FRET analysis, TNP-specific IgE sensitized BMMCs was firstly stained 
by non-blocking anti-CD300a antibody TX10 (Alexa546 conjugated) for 15min and 
then labeled by 500nM NBD-PS in Hank's Balanced Salt Solution (HBSS) with 
1mM CaCl2 for 8min in room temperature. The cells were immediately washed by 5 
mg/ml fatty acid-free Bovine Serum Albumin (BSA) in HBSS with 1mM CaCl2. The 
stained cells were challenged by TNP-OVA and observed under live imaging 
conditions with laser set 471nm/559nm and filter set 490nm-540nm and 570nm-
620nm. 
 
FRET efficiency was calculated by sensitized emission according to the FRET 
package instructions in FV10-ASW (Olympus).  
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Efficiency	(E) = 1 − .. + 01234 ∗ 6Ψ88Ψ99: ∗ (Q8Q9)	 Ψ88,Ψ99: collection efficiency in donor and acceptor channel; Q8, Q9	: Quantum yield of the donor and acceptor; 01234 = = − >?@4 − A?@4 =: Acceptor with donor excitation >?@4 = 6B9: ∗ .							A?@4 = 6C8: ∗ D  
e: Donor with donor excitation D: Acceptor with acceptor excitation 
e, f and D were obtained using donor and acceptor double stained samples 
(FRET samples). 
DSBT (donor spectral bleedthrough) and ASBT (acceptor spectral bleedthrough) 
were calculated by images from the donor/acceptor single stained sample excited by 
designated laser according to the package instruction to obtain the value a, b c and d.  
FRET+ cell percentage was calculated by counting the FRET+ cells in each field. 
 
3.5 Phagocytosis assay 
8-week old mouse were intraperitoneally injected with 2ml thioglycolate. Four days 
later, peritoneal cells were harvested by complete DMEM (10% FBS) and seeded in 
48-well plate. Wash by warm PBS twice before adding degranulated and stained 
BMMC. 
BMMC were sensitized by TNP-specific IgE for two hours and degranulated 
with 10ng/ml TNP-OVA in Tyrode’s buffer for 10min. After degranulation, BMMC 
were washed by warm Tyrode’s buffer and stained by 100ng/ml pHrodo Red 
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(ThermoFisher) in HBSS+1mM CaCl2 for 30min RT, followed by wash with 
complete DMEM (10% FBS). Suspend 106 cells/ml in complete DMEM (10% FBS). 
Add degranulated and stained BMMC into macrophage wells at 1:1 ratio and 
incubate for 60min. The reaction was stopped by aspirating the medium and adding 
1mM EDTA and incubation for another 10min. Macrophages were detached by 
pipetting and stained for CD3e-FITC (145-2C11), CD19-FITC (1D3), NK1.1-FITC 
(PK136), Ly6G-FITC (1A8), KIT-Alexa488 (2B8), F4/80-APC (CI:A3-1), CD11b-
APC-Cy7 (M1/70) with 2.4G2 on ice 30min. Phagocytosis was measured by YG-
PE+ cells in lineage (FITC)-CD11b+F4/80+ gate. 
Apoptotic thymocytes induced by 1µM dexamethasone overnight were used 
as positive controls. 
 
3.6 Passive systemic anaphylaxis 
WT and Cd300a-/- mice (age-matched 8- to 14-week-old females) were sensitized by 
intravenous (i.v.) administration of 5 μg of TNP-specific IgE (BD Biosciences, C38-
2) for 24 h and then i.v. challenged with 40 μg TNP–OVA. Body temperature was 
measured intrarectally at the indicated time points. For antibody blocking, a 
neutralizing anti-CD300a or isotype (400μg/mice) was injected i.p. 5 h before 
antigen challenge. 
For staining ear tissue sections, 50 μg/mice MFG-E8-D89E (Flag-taged) 
were i.v injected together with or without 40μg/mice antigen. Ear tissue was 
harvested 10min after injection and fixed with formalin. Paraffin sections were 
deparaffinized, antigen retrieval was done by using AR6 buffer (PerkinElmer), 
staining for MCs by using FITC-Avidin (Biolegend) and PS by using PE-anti-Flag 
(L5, Biolegend). 
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3.7 Western blot analysis 
One hundred thousand BMMCs were degranulated as described above and 
immediately washed with ice-cold PBS at the indicated time points. Cells were 
stimulated with 1 mM sodium orthovanadate and then lysed with 1% (w/v) NP40. 
The lysates were immunoblotted with antibodies against Syk or phosphorylated Syk. 
 
3.8 Statistical analysis 
Statistical analyses were performed using GraphPad Prism software (GraphPad 
Software). For comparing between two groups, statistical significance was 
determined by 2-tailed unpaired Student t test with or without correction by Holm-
Sidak method. For comparing more than two groups, statistical significance was 
determined by 2way-ANOVA multiple comparisons with Bonferroni's or Sidak's 
test. Error bars indicate SEM except for elsewhere mentioned. 
 
  
 23 
4. Results 
4.1 Characterization of PS exposure during mast cell degranulation 
4.1.1 PS exposure is fast and persistent  
To observe PS externalization on the cell surface of viable MCs, we monitored 
surface PS exposure on TNP-specific IgE sensitized bone marrow-derived cultured 
MCs (BMMCs) by confocal microscopy during stimulation with TNP-OVA in the 
presence of PSVue 643, a fluorescent dye with rapid binding capacity for PS. The 
dye began to accumulate on the cell surface of live BMMCs within 600 s after gentle 
addition of antigen (FcεRI stimulation), whereas the non-stimulated BMMCs 
remained negative for the staining (Fig. 2, A), indicating that PS is externalized 
within 10 min after activation.  
In the time-laps imaging, antigen reached BMMCs through spontaneous 
diffusion because antigen addition must minimize the disturbance of the culture to 
maintain the focus. Therefore, the time after no-mixing antigen addition does not 
reflect the time after the FcεRI stimulation in the imaging culture. To further 
investigate the kinetics of PS exposure during degranulation, A quick mixing of 
antigen and BMMCs was performed immediately after the antigen addition. BMMCs 
were stimulated for indicated time period and transferred into ice cold Tyrode’s 
buffer to stop the degranulation, then PS exposure along with a degranulation marker 
- surface CD107a were measured by flow cytometry. As short as 2 mins after FcεRI 
stimulation, MCs strongly degranulated and externalized PS (Fig. 2, B). Different 
with degranulation marker CD107a, which began to decrease from 8 mins after 
stimulation, the exposed PS on MCs last for more than 6 hours without significant 
decay (Fig. 2, B). The PS exposure is reversible and disappeared 24 hours after 
antigen stimulation (Fig. 2, B), in consistency with the previous report. 
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4.1.2 PS exposure is associated with degranulation  
MCs can be activated by other non-degranulating stimulations, such as LPS and IL-
33; MCs degranulation can also be induced by other stimulators other than FcεRI 
signaling. We tested PS exposure under different stimulations including non-
degranulators LPS and IL-33, and degranulators ATP and inonmycin. Interestingly, 
PS exposure was observed only under degranulation condition (Fig. 3, A and B). 
Both stimulations through TLR-4 by LPS and ST2 by IL-33 failed to induce PS 
externalization (Fig. 3, B). Indeed, the degranulation marker CD107a showed strong 
colocalization on the degranulated MCs with exposed PS (i.e., CD107a+ Annexin-
V+) as observed by imaging flow cytometry, suggesting that PS exposure on the cell 
surface of MCs is associated with degranulation (Fig. 3, B). Together, these data 
demonstrate that PS was promptly exposed together with CD107a during 
degranulation of MCs. 
  
4.1.3 PS+ MCs after degranulation are not subject to phagocytosis 
PS exposure on apoptotic cells serves as an “eat-me” signal for phagocytes 
engulfment. The relative long-time PS exposure (> 6hrs, Fig. 2, B) on stimulated 
MCs raised a question: Can phagocytes engulf PS+ live MCs? 
To test this possibility, BMMCs were degranulated by FcεRI stimulation and 
stained with pHrodo, then co-cultured with mouse thioglycolate-induced peritoneal 
macrophages. No difference of the pHrodo-positive macrophage (CD11b+ F4/80+ 
gated) population was found between degranulated and non-degranulated MCs, 
although macrophages did strongly engulf apoptotic cells (Fig. 4). Therefore, PS+ 
MCs after degranulation are not subject to phagocytosis. 
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4.2 Interactions of exposed PS and PS receptor CD300a during MCs 
degranulation  
4.2.1 Co-localization of CD300a and PS during MCs degranulation  
To investigate the function of exposed PS during MCs degranulation, we focused on 
an inhibitory immunoreceptor for PS, CD300a, which is abundantly expressed on 
MCs. By imaging flow cytometry analysis, we found that both PS and CD300a were 
polarized and co-localized on the cell surface of mouse BMMCs (Annexin V 
stained) 15 min after FcεRI stimulation (Fig. 5, A). Higher magnification images by 
confocal microscopy revealed that the colocalized region of PS and CD300a also 
contained dot-like sub-regions on both mouse BMMCs and cultured human synovial 
MCs after degranulation (Fig. 5, B and C). 
 
4.2.2 Interaction of CD300a and PS during MCs degranulation 
To measure the direct interaction of CD300a and PS during MCs degranulation, 
fluorescence resonance energy transfer (FRET) analysis was performed using NBD-
PS as a donor and a non-neutralizing anti-CD300a antibody (TX10, Fig. 6, A) 
conjugated with Alexa546 as an acceptor. The fluorescent PS (NBD-PS) was 
incorporated into MCs by incubation in RT and non-bounded PS was absorbed by 
1% BSA. FRET efficiency calculated by sensitized emission between CD300a and 
PS was increased after degranulation compared with non-stimulated cells (Fig. 6, B). 
Moreover, treatment with a neutralizing anti-CD300a antibody (EX42) that 
interferes the binding of CD300a with PS (Fig. 6, A) dramatically decreased the 
FRET+ cell number during degranulation (Fig. 6, C), demonstrating the direct cis-
interaction between CD300a and PS in the colocalized region of degranulating MCs. 
These data suggest that PS externalized during degranulation bound to CD300a on 
the same MC. 
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4.3 Functional analysis of PS and CD300a interaction during MCs 
degranulation in vitro 
4.3.1 PS-CD300a interaction inhibits MCs degranulation 
To examine the functional consequence of cis-binding between CD300a and PS, we 
next examined the degranulation of WT and Cd300a-/- BMMCs following 
stimulation of FcεRI by addition of TNP-specific IgE and TNP–OVA. Flow 
cytometry analysis showed that the size of the CD107a+ population was significantly 
larger in Cd300a-/- BMMCs than in WT BMMCs from 8 min (480 s) to 30 min 
(1,800 s) after stimulation (Fig. 7, A and B). Moreover, Cd300a-/- BMMCs produced 
a larger amount of β-hexosaminidase than did WT BMMCs when they were 
analyzed 30 min after stimulation (Fig. 7, C). 
Treatment with a neutralizing anti-CD300a antibody (EX42) increased 
CD107a expression on WT BMMCs to a level comparable to that of Cd300a-/- 
BMMCs (Fig. 7, D). Similarly, a neutralizing anti-human CD300a antibody 
increased the CD107a expression during FcεRI-mediated degranulation of cultured 
human synovial MCs (Fig. 7, E). 
Interestingly, FcεRI stimulation also induced a polarization of FcεRI and 
colocalization of FcεRI with CD300a and PS (Fig. 7, F, G). Thus, the same spatio-
temporal localization of CD300a, PS and FcεRI on MCs might cause CD300a-
mediated suppression of FcεRI-mediated CD107a expression during degranulation. 
Indeed, Syk phosphorylation was higher in Cd300a-/- BMMCs than in WT BMMCs 
after antigen challenge at 10 min (600 s) after FcεRI stimulation, but was 
comparable between WT and Cd300a-/- BMMCs at 2 min (120 s) after stimulation 
(Fig. 7, H), consistent with our observation that degranulation was significantly 
higher in  Cd300a-/- than WT BMMCs at 8 min (480 s), but not 2 min (120 s), after 
FcεRI stimulation (Fig. 7, B). Together, these imaging and functional analyses 
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indicate that the cis-interaction of CD300a with PS suppresses FcεRI-mediated 
signaling for degranulation of MCs. 
 
4.3.2 PS-CD300a interaction-mediated inhibition of MCs degranulation is cell 
intrinsic and cell-cell interaction independent 
To confirm the cell-intrinsic effect of CD300a on degranulation, equal numbers of 
WT and Cd300a-/- BMMCs were mixed and stimulated with TNP-specific IgE and 
TNP–OVA. The CD107a+ population was again observed to be larger in Cd300a-/- 
BMMCs than in WT BMMCs (Fig. 8, A and B). We also measured that the 
population of PI+ dead cells were comparable between the cultures of WT and 
Cd300a-/- BMMCs before and after stimulation of FcεRI (Fig. 8, C). Moreover, even 
in the low concentrations of BMMCs in the culture, in which trans-interactions of 
CD300a with PS were unlikely, Cd300a-/- BMMCs still showed increased 
degranulation compared with WT BMMCs (Fig. 8, D and E). These data suggested 
that the cell-cell interaction-mediated trans-interaction between PS and CD300a had 
little effect of the inhibitory function of CD300a. Therefore, the inhibitory function 
of CD300a on FcεRI-mediated MCs degranulation is dependent on cis-interaction 
between self-PS and CD300a. 
 
4.3.3 cis-interaction of CD300a with PS specifically suppresses FcεRI-mediated 
MCs degranulation  
To gain insight of CD300a-mediated suppression of MCs degranulation induced by 
other degranulator other than FcεRI colligation, we visualized BMMCs by staining 
PS and CD300a after degranulation induction by ATP and ionomycin. Interestingly, 
although PS was promptly exposed after stimulation, CD300a did not aggregate on 
the cell surface therefore did not show polarized colocalization with PS (Fig. 9, A). 
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The degranulation measured by CD107a expression was also comparable between 
WT and Cd300a-/- BMMCs (Fig. 9, B). These data suggest the inhibition of MCs 
degranulation mediated by cis-interaction of CD300a with PS maybe specific to 
FcεRI signaling. 
 
4.4 Phenotype of CD300a deficient mice in a MC-dependent PSA model 
4.4.1 Impaired recovery of CD300a deficient mice in a passive systemic anaphylaxis 
model 
To investigate the in vivo function of CD300a-mediated degranulation suppression, 
we analyzed the role of CD300a in the pathogenesis of passive systemic anaphylaxis. 
WT and Cd300a-/- mice were i.v. injected with TNP-specific IgE, followed by an i.v. 
challenge with TNP–OVA. Although rectal temperature of WT and Cd300a-/- mice 
decreased to a similar level by 20 min (1,200 s) after the challenge, the recovery of 
the rectal temperature after this period was slower in Cd300a-/- mice than in WT 
mice (Fig. 10, A), consistent with the time course of the self-regulation of MCs 
degranulation in vitro by CD300a. Similar results were also observed when mice 
were i.p. injected with a neutralizing anti-CD300a antibody (EX42) (Fig. 10, B), 
suggesting that the CD300a-PS interaction suppressed PSA.  
 
4.4.2 Involvement of MCs CD300a and PS cis-interacting in vivo in a PSA model 
To investigate the possibility of cis-interaction between CD300a and PS on MCs in 
vivo during the course of PSA, Flag-tagged MFG-E8-D89E was intravenously 
injected together with TNP–OVA and ear tissue was harvested 10 min after the 
injection. As expected, polarized PS was detected only in the tissue MCs, rather than 
at regions surrounding MCs, ruling out the possibility of trans-interaction between 
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CD300a and PS in vivo, at least in this model. These results suggest that the cis-
interaction regulated MCs degranulation in vitro as well as in vivo. 
 
4.5 CD300a-mediated inhibition of degranulation is a cell-intrinsic feedback 
mechanism ---- additional evidence from a mathematic modeling approach 
To discriminate between the cell-intrinsic and cell-extrinsic mechanism of 
degranulation inhibition, a system of differential equations was constructed as a 
simplified mathematical representation of a two-cell interacting system (Fig. 11, A). 
System: 
1. The degranulation change of Cell B (DegraB) = IgE signaling of cell B 
(IgeB) – self decay of degranulation product.  E(DegraB)EK = L1	 × 	IgeB(K) − L2	 × 	DegraB(K) 
Or for degranulation change of Cell A, E(DegraA)EK = L1	 × 	IgeA(K) − L2	 × 	DegraA(K) 
where, L1 is the efficiency of IgE signaling causing degranulation; L2 is the 
self decay rate.  
2. The population of mast cell is assumed to be homogenous in response to 
antigen stimulation. IgeA(K) = IgeB(K) 
 
3. The Cell A IgE signaling change = intrinsic inhibition from Cell A itself + 
extrinsic inhibition from Cell B. E(IgeA)EK = −L4	 × 	IgeA(K) − L3	 × 	DegraB(K) 
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Or for IgE signaling change of Cell B, E(IgeB)EK = −L4	 × 	IgeB(K) − L3	 × 	DegraA(K) 
where, L3 is the extrinsic inhibition efficiency and L4 is the intrinsic 
inhibition efficiency. 
 
In this simplified system, both compromised intrinsic- and extrinsic- 
inhibition of MC degranulation gave higher degranulation than the normal system 
before the termination (Fig. 11, B). However, system with compromised intrinsic-
inhibition, as manipulated by decreased  L4, terminated the degranulation at similar 
time point as the Normal system, while system with compromised extrinsic-
inhibition, as manipulated by decreased  L3, had longer time of degranulation and 
terminated at a later time point than the Normal system (Fig. 11, B).  
Interestingly, the Cd300a-/- BMMCs not only showed increased 
degranulation before termination, but also terminate the degranulation at a similar 
time point as WT BMMCs did (Fig. 7, B and Fig. 11, B), representing traits of the 
system of compromised intrinsic-inhibition. Therefore, Cd300a-/- BMMCs is 
impaired of cell-intrinsic but not extrinsic inhibition of degranulation, consistent 
with the notion that PS-CD300a cis-interaction-mediated inhibition of MCs 
degranulation is cell intrinsic and cell-cell interaction independent. 
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5. Discussion  
5.1 Cis vs trans-interaction and their pathophysiological significance 
In current study, we identified a novel regulatory pathway where externalized PS on 
degranulated MCs serve as a cell-intrinsic negative feedback to down-regulate the 
degranulation after the onset by binding to an inhibitory receptor CD300a on the 
same cell, adding another layer of regulation on the MCs degranulation (Fig. 12). 
In contrast with previous report, MCs CD300a-mediated inhibition on TLR-4 
signaling is dependent on trans-interaction between MCs and apoptotic cells in a 
cecal ligation puncture model of sepsis19. Indeed, TLR-4 stimulation did not induce 
the PS exposure on MCs (Fig. 3, B), indicating the distinct ligand origins and 
requirements of CD300a in different MCs activation condition. As shown in the PSA 
model, the PS availability for MCs is restricted to itself, suggesting the probable cis-
interaction between CD300a and PS in vivo. Lack of CD300a-PS cis-interaction 
resulted in impaired recovery of body temperature from this PSA model. Although 
how enhanced MCs degranulation translated into impaired recovery in vivo remains 
intriguing, these results highlight the importance of cis-interaction between CD300a 
and self-PS in the pathogenesis of PSA. Therefore, previous and this study together 
clearly suggested that the relative importance of trans- and cis- interaction between 
receptors and ligands depends on their availability in different pathophysiological 
situations. 
CD300a in this study is an example of cis-interaction mediated self-
regulation of MCs degranulation. MCs express many other receptors on their cell 
surface which have regulatory functions on MCs activation while their natural 
ligands are largely unknow 42,99. The degranulated MCs may express their ligands on 
cell surface as the case of CD300a that a chimeric protein of CD300a extracellular 
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region and human IgG1 constant region (CD300a-Fc) bound to MCs after 
degranulation (Fig. 6, A). Using chimeric protein of other MCs receptors might be 
able to identify candidates functioning in the similar scenario as CD300a during 
MCs degranulation. 
Importantly, given the rich inflammatory mediator and protease content 
released after MCs degranulation, MCs activation is a strong immunogenic and 
maybe disruptive process, therefore should be extensively controlled. However, 
given that MCs distribution in the tissue in a scattered manner3, the ligands of its 
receptors may not be always available without inflammation, highlighting the 
importance of self-regulatory characteristic of MCs in their activation control. 
 
5.2 PS exposure and recovery  
Although PS exposure is a well-established phenomenon after MCs degranulation, 
the detailed kinetics and characteristics are unknown. In this study, we examined 
degranulating MCs by live imaging, imaging flow cytometry and flow cytometry 
with different focus. Live imaging of PS exposure during degranulation identified 
the PS exposure is minutes-scale event (Fig. 2, B) distinct from apoptotic PS 
exposure, which takes hours to occur100.  In addition, imaging flow cytometry 
identified the co-localization of externalized PS and a degranulation marker surface 
CD107a as well as an inhibitory PS receptor CD300a. Interestingly, the co-localized 
areas were often polarized on the cell membrane together with IgE receptors (Fig. 3, 
B, Fig. 5, Fig. 7, F, G), indicating the PS exposure is directly associated with 
degranulation which happened primarily in the vicinity of the initial FcεRI clusters. 
The PS+ area contained both patches-like and dot-like PS+ regions (Fig. 2 and Fig. 5, 
B), suggesting that the externalized PS may come from different source (e.g. inner 
leaflet of plasma membrane, membrane of granules and granule itself). These 
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observations may support the idea that PS is present on the inner membrane of 
intracellular vesicles (e.g. endosomes or secretory granules)101. 
Exposed PS of apoptotic cell is an “eat-me” signal for macrophages. On the 
other hand, PS+ MCs after degranulation cannot be engulfed by phagocytes (Fig. 4), 
even the PS persisted on the membrane for more than 6 hrs after degranulation (Fig. 
2, B). Nonetheless, the MCs internalized PS within 24 hrs after degranulation (Fig. 2, 
B) with unknown machinery94, presumably depend on the flippase activity as 
evidenced in other types of cell62. This MCs specific flippase is of particular interest 
because flippase mutated cells with stable PS exposure can be engulfed by 
phagocytes through TAM receptors87. A stable PS exposure after MCs degranulation 
maybe essential for its engulfment by phagocytes68,73.  
 
5.3 CD300a specificity  
CD300a-PS interaction during MCs degranulation showed specific inhibition on 
FcεRI signaling but not ATP or ionomycin induced degranulation pathways (Fig. 9). 
In a rat basophilic leukemia cell line, transduced CD300a suppresses FcεRI signaling 
by phosphatase recruitment through its ITIM motifs102. In FcεRI mediated 
degranulation, Syk phosphorylation is one of the important targets of CD300a (Fig. 
7, H). It is likely that ATP and ionomycin induced degranulation by causing calcium 
influx directly into the cytoplasm through activation of cation channels and initiate 
degranulation without primary requirement of upstream kinase (e.g. Syk) 
phosphorylation, therefore the inhibitory effect of CD300a was negligible in these 
situations. In contrast with our observation, another inhibitory receptor of CD300 
family, CD300lf, showed modest inhibition of ATP induced MCs degranulation, 
although the targeted signaling pathway remain elusive103. 
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5.4 Technical advances and caveat 
5.4.1 PSVue as degranulation monitoring reagent 
In this study, we frequently used a small molecule PSVue as a probe for PS 
detection. The fast binding of PS and PSVue provided a possibility of real-time 
monitoring of MCs degranulation through its PS exposure. This method is similar 
with previously reported method using fluorochrome-labeled avidin. Further 
comparison might be performed to evaluate both methods in parallel. 
 
5.4.2 Protein-lipid FRET 
FRET is a sensitive and challenging method frequently used to address protein-
protein interactions using FRET parries of fluorescent proteins or fluorophores in 
situ104. However, functional interactions in a biological system are not limited to 
proteins. For example, cells express receptors for lipids (e.g. PS) and carbohydrates 
(e.g. nuclic? acids). However, FRET technique is rarely used to assess these 
interactions in situ, probably due to lack of proper labeling methods of lipids and 
carbohydrates. 
In current study, we utilized a fluorescent labeled lipid NBD-PS as a FRET 
donor and non-neutralizing anti-CD300a antibody (TX10, alexa546 conjugated) as 
an acceptor to perform FRET analysis between CD300a and its natural ligand PS on 
degranulated MCs. We observed FRET signals (sensitized emission) after MCs 
degranulation indicating the direct binding of CD300a and its ligand. Moreover, this 
binding is further confirmed by the dramatic decrease of FRET signals after 
treatment of a neutralizing antibody against CD300a to block PS binding (Fig. 6, C). 
Although NBD-PS did not represent all the PS in MCs, which probably lead to the 
underestimation of all the FRET event, this is the first method to measure in situ 
lipid-protein interactions using FRET. 
 35 
The further modification of this method should consider optimal lipid 
labeling condition and using fluorescence protein-tagged target protein instead of 
fluorescence-conjugated antibody. 
 
5.4.3 Mathematical modeling 
Our mathematical modeling of MCs degranulation reflects the impacts of cell-
intrinsic and extrinsic feedbacks on MCs degranulation process. The system is 
composed of two cells with three differential equations and is capable of simulate the 
differential influence of cell-intrinsic and extrinsic feedbacks on the termination of 
degranulation. It is obvious that the system is over-simplified and further 
modification of this system should increase the complexity of the signaling networks 
and cellular components. Nonetheless, current model provides an additional 
evidence upon our imaging and functional analysis, supporting the cis-interaction 
between CD300a and PS. 
 
5.5 Future directions 
CD300 deficient MCs and mice only showed a modest phenotype in degranulation 
and PSA, respectively, raising possibility of other candidates participating in the 
regulation pathway with similar scenario (negative feedback). In addition, Fc protein 
of certain inhibitory receptors on MCs could bind to degranulated MCs as CD300a-
Fc did (data not shown). Therefore, identifying other candidates by strategy 
described in 5.1 may provide further evidence and the significance of the cis-
interaction mediated negative-feedback in MCs degranulation regulation. 
Other cell types, such as other granulocytes, natural killer cells, cytotoxic T 
cell and neurons, are also capable of degranulation. The presence of such 
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degranulation regulatory machinery in other cell types is of great interest and should 
be systematically investigated.  
 
  
 37 
6. Conclusion  
In conclusion, by combining imaging and functional analysis of MCs degranulation, 
we revealed the physical and functional associations of externalized PS with CD300a 
via cis-interaction on viable MCs during degranulation. Given that MCs are widely 
distributed in many tissues in a scattered manner without contact each other and 
apoptotic cells, such self-regulation of MC degranulation represents a novel strategy 
that MCs evolved to control their own activation, adding another layer of regulation 
in allergic responses (Fig. 12). 
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7. Figures 
 
Fig. 1 FcεRI signaling and inhibitory receptors in MCs degranulation. 
Cross-linking of FcεRI by antigen drives the phosphorylation of Syk by Src family 
kinases. Phosphorylated Syk further phosphorylates protein kinase C (PKC) and 
phospholipase C gamma (PLC γ), resulting in degranulation. The inhibitory 
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receptors play important yet unclear roles in suppressing degranulation through their 
interaction with their natural ligands on neighboring cells, MCs itself or not yet 
identified. 
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Fig. 2 Kinetics of PS exposure during MCs degranulation 
(A) BMMCs were sensitized with TNP-specific IgE and stimulated or not with TNP–
OVA in the presence of PSVue643. Time-lapse montage of BMMCs by confocal 
microscopy shows PS externalization. Dead cells were used as a PSVue-643 
staining positive control. Scale bars, 10 μm.  
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(B) Flow cytometry analysis of cell surface CD107a and PS expression. TNP-
specific IgE sensitized BMMC were stimulated or not by 10 ng/ml TNP-OVA 
for indicated time and stained with CD107a and PSVue on ice then analyzed by 
flow cytometry. 
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Fig. 3 Characterization of PS exposure during MCs activation 
(A) BMMCs were sensitized with TNP-specific IgE, stimulated or not with TNP-
OVA for 15 min, stained with anti-CD107a antibody and annexin V, and 
analyzed by imaging flow cytometry. Representative gating (left) and images of 
single cells from the gate I, II, and III (middle). Colocalization of CD107a and 
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PS was analyzed using bright detail similarity R3 based on images of single cells 
in corresponding gates (right, see section 3.4). 
(B) BMMCs were sensitized with TNP-specific IgE, stimulated with indicated 
reagents for 20 min, stained with anti-CD107a, annexin V and PI, and analyzed 
on the gate of PI- cells by flow cytometry. 
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Fig. 4 PS+ MCs after degranulation are not subject of phagocytosis by macrophage. 
BMMCs were sensitized with TNP-specific IgE and degranulated or not with 10 
ng/ml TNP-OVA, then stained with pHrodoRed, cocultured with peritoneal 
macrophages for one hour. Macrophages after coculture were detached and live 
Lineage- CD11b+ F4/80+ cells were gated for pHrodo+. 
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Fig. 5 Localization of PS and PS-receptor CD300a on degranulated MCs 
(A) BMMCs were sensitized with TNP-specific IgE and stimulated or not with TNP-
OVA for 15 min, then Stained with anti-CD300a and annexin V, and analyzed by 
imaging flow cytometry. Representative gating (left); single cell images (center); 
and colocalization of CD300a and PS analyzed using bright detail similarity R3 
based on images of single cells (see section 3.4) in the indicated gate (right).  
(B) BMMCs were sensitized with TNP-specific IgE, stimulated or not with TNP-OVA 
for 15 min, stained with anti-mouse CD300a, and analyzed in the presence of 
PSVue480 under confocal microscopy.  
(C) Cultured human synovial MCs were sensitized with human IgE, stimulated with 
anti-human IgE or isotype control antibody for 15 min, stained with anti-human 
CD300a, and analyzed in the presence of PSVue480 under confocal microscopy. 
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Fig. 6 FRET measurement between CD300a and PS 
(A) Apoptotic mouse thymocytes induced by treatment with dexamethasone or 
degranulating BMMCs induced by antigen stimulation were incubated with 
MFG-E8-D89E, neutralizing anti-mouse CD300a (EX42), or non-neutralizing 
anti-mouse CD300a (TX10) together with chimeric mouse CD300a-Fc, followed 
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by an PE-conjugated antibody against human IgG and PI, in the presence of 
CaCl2, and analyzed by flow cytometry. 
(B) BMMC was sensitized with TNP-specific IgE, labeled with NBD-PS and non-
neutralizing anti-CD300a antibody (TX10, alexa546 labeled) and stimulated by 
TNP-OVA. FRET analysis between CD300a and PS: representative confocal 
pictures (left) and FRET+ cell quantification (right) (see section 3.4). Scale bars, 
5 μm. Error bars indicate SD. 
(C) FRET analysis of the CD300a-PS interaction on BMMCs as in (B) except that 
the cells were pretreated with either isotype or anti-CD300a neutralizing 
antibody during degranulation. Representative merged image (left) and FRET+ 
cell quantification (right). White arrows indicate FRET+ cells. Scale bars, 50 μm. 
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Fig. 7 Functional interaction between CD300a and PS externalized during 
degranulation of MCs 
(A-C) WT or Cd300a-/- BMMCs were sensitized with TNP-specific IgE and 
stimulated or not with TNP–OVA for 30 min (A, C) or the indicated time (B).  
(A) Representative plots showing CD107a expression on the gate of PI- c-Kit+ cells.  
(B) Kinetics of CD107a expression after antigen stimulation.  
(C) β-hexosaminidase release in the culture after degranulation.  
(D) WT and Cd300a-/- BMMCs were sensitized with anti-TNP IgE and pretreated 
with a neutralizing anti-CD300a antibody or control antibody, followed by 
challenge with TNP-OVA antigen. BMMCs were then analyzed for CD107a 
expression on the gate of PI- c-Kit+ cells by flow cytometry. 
(E) Cultured human synovial MCs were sensitized with human IgE and pretreated 
with a neutralizing anti-human CD300a antibody or control antibody, followed 
by challenge with anti-human IgE, and then analyzed for CD107a expression by 
flow cytometry on the gate of PI- c-Kit+ cells by flow cytometry. 
(F, G) BMMCs were sensitized with TNP-specific IgE, challenged or not with TNP-
OVA antigen for 15 min, then stained with anti-IgE and anti-CD300a antibodies (F), 
or PSVue643 plus either anti-IgE or anti-cKit (G), and analyzed by imaging flow 
cytometry. 
(H) Western blot analysis of Syk phosphorylation in whole cell lysates of 
degranulated WT and Cd300a-/- BMMCs at indicated time points. The relative 
amount of phosphorylated Syk, as determined by densitometry, before and after 
stimulation is also shown. Data are representative of two independent experiments. 
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Fig. 8 Increased degranulation in Cd300a-/- BMMCs is cell intrinsic and independent 
of cell-cell interaction 
(A, B) WT and Cd300a-/- BMMCs were equally mixed and sensitized with TNP-
specific IgE, stimulated with TNP–OVA for 30 min, stained with antibodies against 
CD107a, c-Kit, and CD300a and PI and analyzed by flow cytometry. Data are 
representative plots (A) and the mean CD107a expression (B) showing in WT and 
Cd300a-/- BMMCs. 
(C) WT and Cd300a-/- BMMCs were sensitized with anti-TNP IgE, challenged with 
TNP-OVA for 30 min, stained with anti-c-Kit and PI, and analyzed by flow 
cytometry. 
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(D, E) WT and Cd300a-/- BMMCs were sensitized with anti-TNP IgE, diluted into 
different density (scale 50μm) (D), and then challenged with TNP-OVA for 30 min. 
BMMCs were then stained with antibodies against CD107a and c-Kit and PI, 
analyzed by flow cytometry (E).  
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Fig. 9 ATP and ionomycin induced MCs degranulation  
(A) BMMCs were sensitized with TNP-specific IgE, stimulated with indicated 
reagents for 20 min, stained with anti-CD300a antibody and PSVue643, and 
analyzed by imaging flow cytometry. 
(B) WT and Cd300a-/- BMMCs were stimulated with 0.5 mM ATP or 500 ng/ml 
ionomycin, stained with anti-CD107a, anti-cKit and PI, analyzed by flow 
cytometry. 
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Fig. 10 Involvement of CD300a-PS cis-interaction in a PSA model. 
(A) Change in intrarectal temperature in WT (n = 6) and Cd300a-/- (n = 6) mice 
after i.v. sensitization with TNP-specific IgE, followed by i.v. challenge with 
TNP–OVA. Data are pooled from two experiments and error bars indicate 
SD.  
(B) Change in intrarectal temperature in mice injected i.p. with control (n = 8) or 
anti-CD300a (n = 9) antibody after i.v. sensitization with TNP-specific IgE, 
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followed by i.v. challenge with TNP–OVA. Data are pooled from three 
experiments and error bars indicate SD. 
(C) Immunohistochemistry analysis of PS exposure in MCs during PSA. WT 
mice were sensitized with TNP-specific IgE 24hr before injection of 50 μg 
MFG-E8-D89E (Flag-taged) together with or without 40 μg TNP-OVA 
antigen. Ten min after the injection, ear tissue sections were stained for MCs 
by FITC-conjugated Avidin and for PS by PE-conjugated anti-Flag antibody. 
Scale bars: 50 µm (tissue view) and 5 µm (enlarged cell view). 
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Fig. 11 Mathematical modeling of MCs degranulation with intrinsic and extrinsic 
feedback regulation 
(A) Graphical representation of the two-cell model. 
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(B) System, parameters and results of the model in comparison of experimental data. 
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Fig. 12 Graphical summary 
 
 
 
 
 
 
!"#$%&'((%#'()*&+,$-+(%&.-&/.$
! 0'1-",/("$.+,%$-.11'-#%#'()*23%'45+#/-'6%
! 745+#'8%23%.,$'-"&$%9.$:%.,:.;.$+-<%23*-'&'5$+-%=0>??" ., !"#6
! =0>??"*23%!"#*.,$'-"&$.+,%.,:.;.$#%8'1-",/("$.+,%",8%","5:<("4.#@%
 58 
8. Reference 
1. Baccari, G., Pinelli, C., Santillo, A., Minucci, S. & Rastogi, R. International 
Review of Cell and Molecular Biology. Int Rev Cel Mol Bio 290, 1–53 (2011).  
2. Welle, M. Development, significance, and heterogeneity of mast cells with 
particular regard to the mast cell‐specific proteases chymase and tryptase. Journal of 
Leukocyte Biology 61, 233–245 (1997).  
3. Irani, A., hechter, N., Craig, S., DeBlois, G. & Schwartz, L. Two types of human 
mast cells that have distinct neutral protease compositions. Proceedings of the 
National Academy of Sciences of the United States of America 83, 4464–8 (1986). 
4. Beaven, M. A. Our perception of the mast cell from Paul Ehrlich to now. 
European Journal of Immunology 39, 11–25 (2009).  
5. Moon, T. et al. Advances in mast cell biology: new understanding of 
heterogeneity and function. Mucosal Immunology 3, mi2009136 (2009).  
6. Cass, R., Riley, J., West, G., Head, K. & Stroud, S. Heparin and Histamine in 
Mast-Cell Tumours from Dogs. Nature 174, 174318b0 (1954).  
7. Riley, J. & West, G. Histamine in tissue mast cells. J Physiology 117, 72P-73P 
(1952).  
8. Riley, J. & West, G. The presence of histamine in tissue mast cells. J Physiology 
120, 528–537 (1953).  
9. Ishizaka, K. & Ishizaka, T. Identification of gamma-E-antibodies as a carrier of 
reaginic activity. Journal of immunology (Baltimore, Md. : 1950) 99, 1187–98 
(1967).  
10. Ishizaka, K. & Ishizaka, T. Physicochemical properties of reaginic antibody I. 
Association of reaginic activity with an immunoglobulin other than γA- or γG-
globulin. J Allergy 37, 169–185 (1966).  
11. Barsumian, E. L., Isersky, C., Petrino, M. G. & Siraganian, R. P. IgE‐induced 
histamine release from rat basophilic leukemia cell lines: isolation of releasing and 
 59 
nonreleasing clones. European Journal of Immunology 11, 317–323 (1981).  
12. Kulczycki, A., Isersky, C. & Metzger, H. The Interaction of IgE with Rat 
Basophilic Leukemia Cells I. Evidence for Specific Binding of IgE. The Journal of 
Experimental Medicine 139, 600–616 (1974).  
13. Blank, U. et al. Complete structure and expression in transfected cells of high 
affinity IgE receptor. Nature 337, 337187a0 (1989).  
14. Moon, T., Befus, D. A. & Kulka, M. Mast Cell Mediators: Their Differential 
Release and the Secretory Pathways Involved. Frontiers in Immunology 5, (2014).  
15. Mukai, K., Tsai, M., Saito, H. & Galli, S. J. Mast cells as sources of cytokines, 
chemokines, and growth factors. Immunological Reviews 282, 121–150 (2018).  
16. Johnzon, C.-F., Rönnberg, E. & Pejler, G. The Role of Mast Cells in Bacterial 
Infection. The American Journal of Pathology 186, 4–14 (2016).  
17. Nardo, A., Yamasaki, K., Dorschner, R. A., Lai, Y. & Gallo, R. L. Mast Cell 
Cathelicidin Antimicrobial Peptide Prevents Invasive Group A Streptococcus 
Infection of the Skin. The Journal of Immunology 180, 7565–7573 (2008).  
18. Mekori, Y. A. & Metcalfe, D. D. Mast cells in innate immunity. Immunological 
Reviews 173, 131–140 (2000).  
19. Nakahashi-Oda, C. et al. Apoptotic cells suppress mast cell inflammatory 
responses via the CD300a immunoreceptor. The Journal of experimental medicine 
209, 1493–503 (2012).  
20. Galli, S. J., Nakae, S. & Tsai, M. Mast cells in the development of adaptive 
immune responses. Nature Immunology 6, 135–142 (2005).  
21. Feyerabend, T. B. et al. Cre-Mediated Cell Ablation Contests Mast Cell 
Contribution in Models of Antibody- and T Cell-Mediated Autoimmunity. Immunity 
35, 832–844 (2011).  
22. Grimbaldeston, M. A. et al. Mast cell-deficient W-sash c-kit mutant Kit W-
 60 
sh/W-sh mice as a model for investigating mast cell biology in vivo. The American 
journal of pathology 167, 835–48 (2005).  
23. Yagi, R., Tanaka, S., Motomura, Y. & Kubo, M. Regulation of the Il4 Gene Is 
Independently Controlled by Proximal and Distal 3’ Enhancers in Mast Cells and 
Basophils. Molecular and Cellular Biology 27, 8087–8097 (2007).  
24. Strait, R. T., Morris, S. C., Yang, M., Qu, X.-W. & Finkelman, F. D. Pathways 
of anaphylaxis in the mouse. Journal of Allergy and Clinical Immunology 109, 658–
668 (2002).  
25. Hitomi, K. et al. An immunoglobulin-like receptor, Allergin-1, inhibits 
immunoglobulin E–mediated immediate hypersensitivity reactions. Nature 
Immunology 11, ni.1886 (2010).  
26. Kraft, S. et al. The Tetraspanin CD63 Is Required for Efficient IgE-Mediated 
Mast Cell Degranulation and Anaphylaxis. The Journal of Immunology 191, 2871–
2878 (2013).  
27. Wang, M. et al. Peanut-induced intestinal allergy is mediated through a mast 
cell–IgE–FcεRI–IL-13 pathway. Journal of Allergy and Clinical Immunology 126, 
306-316.e12 (2010).  
28. Ushio, H. et al. Crucial role for autophagy in degranulation of mast cells. Journal 
of Allergy and Clinical Immunology 127, 1267-1276. e6 (2011).  
29. Abbas, A. K., Lichtman, A. H. & Shiv. Cellular and Molecular Immunology. 
Elsevier (Elsevier).  
30. Lagunoff, D. & Benditt, E. P. Mast Cell Degranulation and Histamine Release 
Observed in a New in vitro System. The Journal of Experimental Medicine 112, 
571–580 (1960).  
31. Mazingue, C., Dessaint, J.-P. & Capron, A. [3H] serotonin release: An improved 
method to measure mast cell degranulation. Journal of Immunological Methods 21, 
 61 
65–77 (1978).  
32. Razin, E. et al. IgE-mediated release of leukotriene C4, chondroitin sulfate E 
proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-
derived mouse mast cells. The Journal of Experimental Medicine 157, 189–201 
(1983).  
33. Grützkau, A. et al. LAMP‐1 and LAMP‐2, but not LAMP‐3, are reliable markers 
for activation‐induced secretion of human mast cells. Cytometry Part A 61A, 62–68 
(2004).  
34. Kawakami, T. et al. Deficient Autophagy Results in Mitochondrial Dysfunction 
and FSGS. Journal of the American Society of Nephrology 26, 10401052 (2014).  
35. Xiao, W. et al. Positive and negative regulation of mast cell activation by Lyn 
via the FcεRI. The Journal of Immunology 175, 6885–6892 (2005).  
36. Odom, S. et al. Negative Regulation of Immunoglobulin E–dependent Allergic 
Responses by Lyn Kinase. J Exp Medicine 199, 1491–1502 (2004).  
37. Nishizumi, H. & Yamamoto, T. Impaired tyrosine phosphorylation and Ca2+ 
mobilization, but not degranulation, in lyn-deficient bone marrow-derived mast cells. 
The Journal of Immunology 158, 2350–2355 (1997).  
38. Hernandez-Hansen, V. et al. Dysregulated FcεRI Signaling and Altered Fyn and 
SHIP Activities in Lyn-Deficient Mast Cells. J Immunol 173, 100–112 (2004).  
39. Zhang, J., Berenstein, E., Evans, R. & Siraganian, R. Transfection of Syk protein 
tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a 
Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. The Journal of 
Experimental Medicine 184, 71–79 (1996).  
40. Wang, D. et al. Phospholipase Cγ2 Is Essential in the Functions of B Cell and 
Several Fc Receptors. Immunity 13, 25–35 (2000).  
41. Finkelman, F. D. Anaphylaxis: Lessons from mouse models. Journal of Allergy 
 62 
and Clinical Immunology 120, 506–515 (2007).  
42. Bulfone-Paus, S., Nilsson, G., Draber, P., Blank, U. & Levi-Schaffer, F. Positive 
and Negative Signals in Mast Cell Activation. Trends in Immunology 38, 657–667 
(2017).  
43. Galli, S. J. et al. Mast cells as “tunable” effector and immunoregulatory cells: 
recent advances. Annu Rev Immunol 23, 749–786 (2005).  
44. Gilfillan, A. M. & Rivera, J. The tyrosine kinase network regulating mast cell 
activation. Immunological Reviews 228, 149–169 (2009).  
45. Molderings, G. J. et al. Pharmacological treatment options for mast cell 
activation disease. Naunyn-Schmiedeberg’s Archives of Pharmacology 389, 671–694 
(2016).  
46. Föger, N. et al. Differential regulation of mast cell degranulation versus cytokine 
secretion by the actin regulatory proteins Coronin1a and Coronin1b. The Journal of 
Experimental Medicine 208, 1777–1787 (2011).  
47. Lorentz, A., Baumann, A., Vitte, J. & Blank, U. The SNARE Machinery in Mast 
Cell Secretion. Frontiers in Immunology 3, 143 (2012).  
48. Metcalfe, D. D., Peavy, R. D. & Gilfillan, A. M. Mechanisms of mast cell 
signaling in anaphylaxis. Journal of Allergy and Clinical Immunology 124, 639–646 
(2009).  
49. Baker, R. W. & Hughson, F. M. Chaperoning SNARE assembly and 
disassembly. Nat Rev Mol Cell Bio 17, 465–479 (2016).  
50. Kneussel, M. & Wagner, W. Myosin motors at neuronal synapses: drivers of 
membrane transport and actin dynamics. Nat Rev Neurosci 14, 233 (2013).  
51. Robbie-Ryan, M., Tanzola, M. B., Secor, V. H. & Brown, M. A. Cutting edge: 
both activating and inhibitory Fc receptors expressed on mast cells regulate 
experimental allergic encephalomyelitis disease severity. Journal of immunology 
 63 
(Baltimore, Md. : 1950) 170, 1630–4 (2003).  
52. Katz, H. et al. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-
based inhibition motifs and suppresses mast cell activation when coligated with the 
high-affinity Fc receptor for IgE. Proceedings of the National Academy of Sciences 
of the United States of America 93, 10809–14 (1996).  
53. Liénard, H., Bruhns, P., Malbec, O., Fridman, W. & ëron. Signal regulatory 
proteins negatively regulate immunoreceptor-dependent cell activation. The Journal 
of biological chemistry 274, 32493–9 (1999).  
54. Masuda, A., Nakamura, A., Maeda, T., Sakamoto, Y. & Takai, T. Cis binding 
between inhibitory receptors and MHC class I can regulate mast cell activation. The 
Journal of Experimental Medicine 204, 907–920 (2007).  
55. Yotsumoto, K. et al. Paired Activating and Inhibitory Immunoglobulin-like 
Receptors, MAIR-I and MAIR-II, Regulate Mast Cell and Macrophage Activation. 
The Journal of Experimental Medicine 198, 223–233 (2003).  
56. Yamanishi, Y. et al. A soluble form of LMIR5/CD300b amplifies 
lipopolysaccharide-induced lethal inflammation in sepsis. Journal of immunology 
(Baltimore, Md. : 1950) 189, 1773–9 (2012).  
57. Izawa, K. et al. The Receptor LMIR3 Negatively Regulates Mast Cell Activation 
and Allergic Responses by Binding to Extracellular Ceramide. Immunity 37, 827–
839 (2012).  
58. Cooper, G. The Cell - A Molecular Approach 2nd Edition. The Cell - A 
Molecular Approach 2nd Edition (Sunderland (MA): Sinauer Associates).  
59. van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they 
are and how they behave. Nature Reviews Molecular Cell Biology 9, 112–124 
(2008).  
60. van Meer, G. & de Kroon, A. Lipid map of the mammalian cell. Journal of Cell 
 64 
Science 124, 5–8 (2011).  
61. igneuret & Devaux, P. ATP-dependent asymmetric distribution of spin-labeled 
phospholipids in the erythrocyte membrane: relation to shape changes. Proceedings 
of the National Academy of Sciences 81, 3751–3755 (1984).  
62. Nagata, S. Apoptosis and Clearance of Apoptotic Cells. Annual Review of 
Immunology 36, 1–29 (2018).  
63. Elliott, J. I. et al. Phosphatidylserine exposure in B lymphocytes: a role for lipid 
packing. Blood 108, 1611–7 (2006).  
64. Elliott, J. I. et al. Membrane phosphatidylserine distribution as a non-apoptotic 
signaling mechanism in lymphocytes. Nature Cell Biology 7, 808–816 (2005).  
65. Lentz, B. R. Exposure of platelet membrane phosphatidylserine regulates blood 
coagulation. Progress in Lipid Research 42, 423–438 (2003).  
66. Martin, S. et al. Immunologic stimulation of mast cells leads to the reversible 
exposure of phosphatidylserine in the absence of apoptosis. Int Arch Allergy Imm 
123, 249–258 (2000).  
67. Bevers, E. M. & Williamson, P. L. Phospholipid scramblase: An update. FEBS 
Letters 584, 2724–2730 (2010).  
68. Nagata, S., Suzuki, J., Segawa, K. & Fujii, T. Exposure of phosphatidylserine on 
the cell surface. Cell Death Differ 23, 952–961 (2016).  
69. Segawa, K. et al. Caspase-mediated cleavage of phospholipid flippase for 
apoptotic phosphatidylserine exposure. Science 344, 1164–1168 (2014).  
70. Suzuki, J., Denning, D. P., Imanishi, E., Horvitz, R. H. & Nagata, S. Xk-Related 
Protein 8 and CED-8 Promote Phosphatidylserine Exposure in Apoptotic Cells. 
Science 341, 403–406 (2013).  
71. Fujii, T., Sakata, A., Nishimura, S., Eto, K. & Nagata, S. TMEM16F is required 
for phosphatidylserine exposure and microparticle release in activated mouse 
 65 
platelets. Proceedings of the National Academy of Sciences 112, 12800–12805 
(2015).  
72. Segawa, K., Suzuki, J. & Nagata, S. Constitutive exposure of phosphatidylserine 
on viable cells. Proceedings of the National Academy of Sciences 108, 19246–19251 
(2011).  
73. Segawa, K. & Nagata, S. An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine 
Exposure. Trends in Cell Biology 25, 639–650 (2015).  
74. Toda, S., Nishi, C., Yanagihashi, Y., Segawa, K. & Nagata, S. Current Topics in 
Developmental Biology. Curr Top Dev Biol 114, 267–295 (2015).  
75. van der Meer, J. H., van der Poll, T. & van Veer, C. TAM receptors, Gas6, and 
protein S: roles in inflammation and hemostasis. Blood 123, 2460–2469 (2014).  
76. Krahling, S., Callahan, M. K., Williamson, P. & Schlegel, R. A. Exposure of 
phosphatidylserine is a general feature in the phagocytosis of apoptotic lymphocytes 
by macrophages. Cell Death Differ 6, 4400473 (1999).  
77. Asano, K. et al. Masking of phosphatidylserine inhibits apoptotic cell engulfment 
and induces autoantibody production in mice. J Exp Medicine 200, 459–467 (2004).  
78. Hanayama, R. et al. Identification of a factor that links apoptotic cells to 
phagocytes. Nature 417, 182–7 (2002).  
79. Toda, S., Hanayama, R. & Nagata, S. Two-Step Engulfment of Apoptotic Cells. 
Molecular and Cellular Biology 32, 118–125 (2012).  
80. Yanagihashi, Y., Segawa, K., Maeda, R., Nabeshima, Y. & Nagata, S. Mouse 
macrophages show different requirements for phosphatidylserine receptor Tim4 in 
efferocytosis. Proceedings of the National Academy of Sciences 114, 8800–8805 
(2017).  
81. Dransfield, I., Zagórska, A., Lew, E., Michail, K. & Lemke, G. Mer receptor 
tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells. Cell 
 66 
Death & Disease 6, e1646 (2015).  
82. Nakahashi-Oda, C. et al. Apoptotic epithelial cells control the abundance of Treg 
cells at barrier surfaces. Nature Immunology (2016). doi:10.1038/ni.3345  
83. Savill, J., Dransfield, I., Gregory, C. & Haslett, C. A blast from the past: 
clearance of apoptotic cells regulates immune responses. Nature Reviews 
Immunology 2, nri957 (2002).  
84. Flannagan, R. S., Canton, J., Furuya, W., Glogauer, M. & Grinstein, S. The 
phosphatidylserine receptor TIM4 utilizes integrins as coreceptors to effect 
phagocytosis. Molecular Biology of the Cell 25, 1511–1522 (2014).  
85. Park, S.-Y., Bae, D.-J., Kim, M.-J., Piao, M. & Kim, I.-S. Extracellular Low pH 
Modulates Phosphatidylserine-dependent Phagocytosis in Macrophages by 
Increasing Stabilin-1 Expression. J Biol Chem 287, 11261–11271 (2012).  
86. Schroit, A. & Fidler, I. Effects of liposome structure and lipid composition on the 
activation of the tumoricidal properties of macrophages by liposomes containing 
muramyl dipeptide. Cancer Res 42, 161–7 (1982).  
87. Segawa, K. et al. Phospholipid flippases enable precursor B cells to flee 
engulfment by macrophages. Proc National Acad Sci 115, 201814323 (2018).  
88. Krishnaswamy, S. Prothrombinase complex assembly. Contributions of protein-
protein and protein-membrane interactions toward complex formation. The Journal 
of biological chemistry 265, 3708–18 (1990).  
89. Jones, M. E., Lentz, B. R., Dombrose, F. A. & Sandberg, H. Comparison of the 
abilities of synthetic and platelet-derived membranes to enhance thrombin formation. 
Thrombosis Research 39, 711–724 (1985).  
90. Dillon, S. R., Constantinescu, A. & Schlissel, M. S. Annexin V Binds to 
Positively Selected B Cells. J Immunol 166, 58–71 (2001).  
91. Dillon, S. R., Mancini, M., Rosen, A. & Schlissel, M. S. Annexin V Binds to 
 67 
Viable B Cells and Colocalizes with a Marker of Lipid Rafts upon B Cell Receptor 
Activation. J Immunol 164, 1322–1332 (2000).  
92. Demo, S. et al. Quantitative measurement of mast cell degranulation using a 
novel flow cytometric annexin-V binding assay. Cytometry 36, 340–8 (1999).  
93. Smrž, D., Dráberová, L. & Dráber, P. Non-apoptotic Phosphatidylserine 
Externalization Induced by Engagement of Glycosylphosphatidylinositol-anchored 
Proteins. J Biol Chem 282, 10487–10497 (2007).  
94. Rysavy, N. M. et al. Beyond apoptosis: the mechanism and function of 
phosphatidylserine asymmetry in the membrane of activating mast cells. 
Bioarchitecture 4, 127–37 (2014).  
95. Nakahashi-Oda, C., Tahara-Hanaoka, S., Honda, S., Shibuya, K. & Shibuya, A. 
Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor. 
Biochemical and Biophysical Research Communications 417, 646–650 (2012).  
96. Poon, I. K., Lucas, C. D., Rossi, A. G. & Ravichandran, K. S. Apoptotic cell 
clearance: basic biology and therapeutic potential. Nature Reviews Immunology 14, 
166–180 (2014).  
97. Okoshi, Y. et al. Requirement of the tyrosines at residues 258 and 270 of MAIR-
I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. 
International immunology 17, 65–72 (2004).  
98. Lee, H. et al. Activation of human synovial mast cells from rheumatoid arthritis 
or osteoarthritis patients in response to aggregated IgG through Fcγ receptor I and 
Fcγ receptor II. Arthritis and rheumatism 65, 109–19 (2013).  
99. Harvima, I. T. et al. Molecular targets on mast cells and basophils for novel 
therapies. The Journal of allergy and clinical immunology 134, 530–44 (2014).  
100. Gelles, J. D. & Chipuk, J. Robust high-throughput kinetic analysis of apoptosis 
with real-time high-content live-cell imaging. Cell Death Dis 7, e2493 (2016).  
 68 
101. Leventis, P. A. & Grinstein, S. The distribution and function of 
phosphatidylserine in cellular membranes. Annu Rev Biophys 39, 407–427 (2010).  
102. Okoshi, Y. et al. Requirement of the tyrosines at residues 258 and 270 of 
MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. 
International immunology 17, 65–72 (2005).  
103. Matsukawa, T. et al. Ceramide-CD300f binding suppresses experimental colitis 
by inhibiting ATP-mediated mast cell activation. Gut 65, gutjnl-2014-308900 
(2015).  
104. Lalevée, S., Ferry, C. & Rochette-Egly, C. Transcription Factors, Methods and 
Protocols. Methods Mol Biology Clifton N J 647, 251–266 (2010).  
 
  
 69 
9. Acknowledgement  
This dissertation work is performed in the Department of immunology in University 
of Tsukuba, where fantastic scientists gather and push the boundary of science. This 
dissertation will not be possible without the generous help from them. 
I would like to express my deepest gratitude to my mentors Dr. Akira 
Shibuya and Dr. Nakahashi-Oda Chigusa. Their dedication to CD300a biology is the 
most critical determinant for the outcome of this project. Their passion of science, 
persistence on critical thinking, sense of novelty, precision of judgement and more 
constitute the most important mentorship I have ever experienced and benefited 
from. I am very grateful to this four-and-half-year training under their guidance and I 
believe their imprinting on me will continue benefit to my future career.  
This PhD will not be possible without the continuous support from the lab 
community with sharing reagents, protocols, ideas and so on. Actually, it was during 
a casual chatting after dinner in the lab, the key idea of this project bubbled out. 
Specifically, I would like to thank Dr. Fujiyama Satoshi, Dr. Kazumasa Kanemaru, 
Dr. Tsukasa Nabekura, Mr. Yuuta Nakazawa and Ms. Mariana Silva Almeida for 
their generous help at any time upon my request, both mentally and scientifically. 
Last but not least, I want to thank my beloved families, dad and mum, and 
my girlfriend, Wenjun. Without them, I could not have survived the difficult periods 
during this PhD. Their encouraging and caring always keep me moving forward. 
 
 
 70 
10. Abbreviation 
  
ATP Adenosine triphosphate 
ATP11C ATPase Phospholipid Transporting 11C 
BMMC Bone marrow dirived mast cell 
FceRI High-affinity IgE receptor I 
FRET Fluorescence resonance energy transfer 
IgE Immunoglobulin E 
ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibition motif  
MC Mast cell 
MHC Major histocompatibility complex 
NBD-PS 
1,2-dioleoyl-sn-glycero-3-phospho-L-serine-N-(7-nitro-2-1,3-
benzoxadiazol-4-yl 
PA Phosphatidic acid 
PC phosphatidylcholine 
PE Phosphatidylethanolamine 
PI Phosphatidylinositol 
PS Phosphatidylserine 
PSA Passive systemic anaphylaxis 
SHIP Src homology region 2 containing inositol phosphatase 
SHP Src homology region 2 domain-containing phosphatase-1 
TNF Tumor necrosis factor  
